<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18743" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, C Peptide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Venugopal</surname>
            <given-names>Senthil K.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mowery</surname>
            <given-names>Myles L.</given-names>
          </name>
          <aff>Kansas City University of Medicine and Biosciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jialal</surname>
            <given-names>Ishwarlal</given-names>
          </name>
          <aff>VA MEDICAL CENTER, MATHER , CA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Senthil Venugopal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Myles Mowery declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18743.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>C-peptide (connecting peptide) connects alpha and beta chains of proinsulin, which are&#x000a0;formed in the endoplasmic reticulum following the removal of the signal peptide of pre-proinsulin. It is secreted from the beta cells of islets of Langerhans of the endocrine pancreas when proinsulin is cleaved into insulin and C-peptide. It plays an important role in the correct folding of insulin and the formation of disulfide bridges. C-peptide is removed in the Golgi apparatus from proinsulin resulting in the formation of the mature insulin molecule with both alpha and beta chains bound together&#x000a0;by disulfide bonds.<xref ref-type="bibr" rid="article-18743.r1">[1]</xref>&#x000a0;Both insulin and C-peptide are stored in secretory vesicles and released in equimolar concentrations upon stimulation of beta cells by glucose and other secretagogues.<xref ref-type="bibr" rid="article-18743.r2">[2]</xref>&#x000a0;The most important indications for&#x000a0;measurement of C-peptide levels include the differential diagnosis of fasting hypoglycemia with hyperinsulinism and as a measure of insulin secretory reserve. This brief review&#x000a0;covers the relevant biochemistry, measurement, and clinical indications.</p>
      </sec>
      <sec id="article-18743.s2" sec-type="Fundamentals">
        <title>Fundamentals</title>
        <p>Once secreted, both insulin and C-peptide are routed through the liver. In the liver, insulin binds to its receptors and initiates glucose uptake, inhibits gluconeogenesis, glycogenolysis, and ketogenesis and is degraded within 5 to 10 minutes. C-peptide, on the other hand, has limited degradation in the liver and is degraded by the kidneys. Hence, the half-life of C-peptide is around 30 to 35 minutes. As a result, although both insulin and C-peptide are secreted in equimolar concentrations, the molar ratio of circulating insulin to C-peptide is less than 1. Several studies have shown that C-peptide can bind to the cell membranes and could exert biological effects; however, a specific receptor has not been identified, and this is described later.</p>
      </sec>
      <sec id="article-18743.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>The normal physiological C-peptide plasma concentration in a fasted state is 0.9 to 1.8 ng/ml.<xref ref-type="bibr" rid="article-18743.r1">[1]</xref>&#x000a0;A high level could indicate insulin resistance, insulinoma, or kidney disease. A low C-peptide is usually present in patients with type 1, or sometimes, type 2 diabetes.</p>
      </sec>
      <sec id="article-18743.s4" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>C-peptide is a 31-amino acid polypeptide and is negatively charged. In mammals, the 8 residues (positions 1, 3, 6, 11, 12, 21, 27, and 31) are conserved, and the C-terminal pentapeptide has been shown to interact with the cell membrane and elicit signaling pathways.<xref ref-type="bibr" rid="article-18743.r3">[3]</xref>&#x000a0;Although the exact mechanism of binding is not known, the binding characteristics and the intracellular effects could be modified by pertussis toxin, suggesting that the G-protein coupled receptors might be involved.<xref ref-type="bibr" rid="article-18743.r4">[4]</xref>&#x000a0;The binding of C-peptide was shown to elevate the intracellular calcium levels. It also can induce phospholipase C, protein kinase C isoforms, Rho A,&#x000a0; and p38 MAPK in renal tubular cells and fibroblasts.<xref ref-type="bibr" rid="article-18743.r5">[5]</xref>&#x000a0;Activation of the PI3 kinase, Akt, and PPAR-gamma&#x000a0;is also observed in fibroblasts, myoblasts, renal tubular cells, and lymphocytes.<xref ref-type="bibr" rid="article-18743.r6">[6]</xref>&#x000a0;In endothelial cells, C-peptide was shown to induce nitric oxide release by enhancing the expression of eNOS mRNA and protein in aortic endothelial cells. It was also shown to stimulate Na, K-ATPase in renal tubular cells in vitro.<xref ref-type="bibr" rid="article-18743.r5">[5]</xref>&#x000a0;</p>
        <p>C-peptide was also shown to possess several anti-inflammatory, cytoprotective, and anti-apoptotic effects in various cell types. Under physiological conditions, C-peptide was shown to inhibit the formation of reactive oxygen species (ROS) via RAC1-mediated inhibition of NAD(P)H oxidase in endothelial cells of streptozotocin (STZ)-diabetic mice.<xref ref-type="bibr" rid="article-18743.r7">[7]</xref>&#x000a0;C-peptide could inhibit ROS-mediated activation of transglutaminase 2, thereby&#x000a0;inhibiting apoptosis. It also exerted the anti-apoptotic effect by inhibiting caspase 3 activation and enhancing the anti-apoptotic protein, BCL-2 in endothelial cells and neuroblastoma cells. C-peptide was also shown to inhibit the inflammatory pathway by the downregulation of NF-kB. It was also shown that C-peptide could decrease the expression of high glucose-induced ICAM, VCAM, and P-selectin.<xref ref-type="bibr" rid="article-18743.r8">[8]</xref>&#x000a0;High glucose-induced, vascular, smooth muscle cell proliferation and migration may be inhibited by the presence of&#x000a0;C-peptide,&#x000a0;thereby&#x000a0;causing the inhibition of atherosclerotic lesion formation.<xref ref-type="bibr" rid="article-18743.r9">[9]</xref>&#x000a0;There is considerable interest in the biology of C-peptide, its elusive receptor, and biological effects in humans. However, this body of data is largely&#x000a0;experimental and needs much further research in the clinical area to gain mainstream support.</p>
      </sec>
      <sec id="article-18743.s5" sec-type="Testing">
        <title>Testing</title>
        <p>As C-peptide is&#x000a0;released in the circulation along with insulin, it has widely been used as&#x000a0;a measure of insulin secretion to assess the pancreatic beta-cell function.<xref ref-type="bibr" rid="article-18743.r10">[10]</xref>&#x000a0;It also has the advantage of bypassing clearance by the liver, unlike insulin, and hence, has a much longer half-life of around 30 minutes. The plasma concentration of C-peptide in a fasted state is 0.9 to 1.8 ng/ml, and the postprandial levels are 3 to 9 ng/m in healthy individuals.<xref ref-type="bibr" rid="article-18743.r1">[1]</xref>&#x000a0;The higher levels are observed in overweight individuals. C-peptide is catabolized in the kidneys, and only a small fraction is excreted in the urine. Modern ultrasensitive C-peptide immunoassays can detect plasma levels as low as 0.0045 to 0.0075 ng/ml. The presence of increased titers of anti-insulin antibodies that bind to both proinsulin and C-peptide could give false-positive results. Urinary C-peptide (UCP) measurement is a non-invasive test, and the urine can be collected in boric acid, where UCP is stable at room temperature for up to 3 days. With normal urinary function, the UCP excretion is reflective of 5% to 10% of total C-peptide secreted by the pancreas.<xref ref-type="bibr" rid="article-18743.r11">[11]</xref></p>
        <p>Since C-peptide is a polypeptide and less stable due to its susceptibility to enzymatic proteolytic cleavage, the serum C-peptide measurements should be done immediately after the sample collection. Hence, gel tubes are required to collect samples on ice to transport the sample to the laboratory. The samples should be immediately centrifuged and stored under frozen conditions until the estimation is done. However, EDTA-prepared tubes can be used for plasma C-peptide determination, which increases its stability at room temperature for up to 24 hours, and hence, plasma is the preferred sample.<xref ref-type="bibr" rid="article-18743.r12">[12]</xref></p>
        <p>The plasma C-peptide levels can be measured in random, fasting (8 to 10 hours) or stimulated state. Random non-fasting sampling (rCP) is the easiest method to test C-peptide (fCP) levels. The rCP has been shown to correlate with 90-minute mixed meal tolerance test (MMTT) C-peptide responses. The stimulation can be done using glucagon, intravenous/oral glucose, tolbutamide, sulfonylurea, and glucagon-like peptide 1, amino acids, or a mixed meal. Glucagon stimulation test (GST) is the most widely used test due to its high sensitivity in detecting residual insulin secretion using a dose of 1.0 mg. C-peptide can also be measured using the oral glucose tolerance test (75 g, OGTT) where the samples are collected at 0, 30, 60, 90, and 120 minutes.<xref ref-type="bibr" rid="article-18743.r13">[13]</xref>&#x000a0;This test significantly correlates with insulin secretion in type 2 diabetes patients. Both MMTT and GST provide sensitive and reproducible results for residual beta-cell function in type 1 diabetes with peak responses seen at 90 and 6 minutes, respectively.<xref ref-type="bibr" rid="article-18743.r14">[14]</xref>&#x000a0;Although the C-peptide levels are useful to classify diabetes, it always must be interpreted in the clinical context of&#x000a0;disease duration, comorbidities, and family history. However, it is still a very valid measure in clinical research studies.</p>
      </sec>
      <sec id="article-18743.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The 2 major indications for measuring C-peptide levels include fasting hypoglycemia and assessment of insulin secretory reserve in patients with diabetes. In patients with fasting hypoglycemia with concomitant hyperinsulinism, one needs to entertain a differential diagnosis comprising insulinoma, exogenous insulin administration (factitious), sulfonylurea therapy (factitious), insulin autoimmune syndrome due to endogenous anti-insulin antibodies (Hirata disease).<xref ref-type="bibr" rid="article-18743.r15">[15]</xref>&#x000a0;All of these conditions can result in hypoglycemia with elevated insulin levels. A C-peptide level is very&#x000a0;useful in the differential diagnosis since it is only elevated with a beta cell tumor, insulinoma, and sulfonylurea therapy. A sulfonylurea drug screen can exclude the latter. C-peptide is not elevated with Hirata disease, which is confirmed by positive anti-insulin antibodies and is decreased with factious, exogenous insulin therapy. Hence, it is a very important test in the workup of fasting hypoglycemia with hyperinsulinism.</p>
        <p>The other major indication is the assessment of insulin secretory reserve in patients with diabetes. Diabetes mellitus is characterized by hyperglycemia due to the lack of insulin secretion and/or insulin action. Insulin deficiency is associated with C-peptide-deficiency in type 1 diabetes due to beta-cell demise. A fasting C-peptide level of less than 0.6 ng/ml is consistent with beta-cell failure and predicts the requirement for insulin therapy. Although the origins of type 2 diabetes are insulin resistance, it only manifests clinically when there is beta-cell failure resulting in impaired insulin and C-peptide secretion culminating in fasting and postprandial hyperglycemia. Much more research is needed to define the biology of C-peptide and potential role in the pathogenesis of diabetic microvascular complications or as a novel therapeutic agent.&#x000a0;</p>
        <p>Also, Medicare uses a C-peptide assessment of insulin reserve as a criterion for continuous subcutaneous insulin infusion therapy (insulin pump therapy).</p>
        <p>
<bold>Pearls</bold>
</p>
        <p>C-peptide is secreted in equimolar concentrations with insulin from the beta cells.</p>
        <p>It is a valid measure of insulin secretion especially following challenges with glucagon or a mixed meal.</p>
        <p>C-peptide is extremely&#x000a0;useful in the differential diagnosis of hyperinsulinemic-hypoglycemia.</p>
      </sec>
      <sec id="article-18743.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18743&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18743">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18743/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18743">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18743.s8">
        <title>References</title>
        <ref id="article-18743.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yosten</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Maric-Bilkan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Luppi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wahren</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Physiological effects and therapeutic potential of proinsulin C-peptide.</article-title>
            <source>Am J Physiol Endocrinol Metab</source>
            <year>2014</year>
            <month>Dec</month>
            <day>01</day>
            <volume>307</volume>
            <issue>11</issue>
            <fpage>E955</fpage>
            <page-range>E955-68</page-range>
            <pub-id pub-id-type="pmid">25249503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steiner</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spigelman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aten</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Insulin biosynthesis: evidence for a precursor.</article-title>
            <source>Science</source>
            <year>1967</year>
            <month>Aug</month>
            <day>11</day>
            <volume>157</volume>
            <issue>3789</issue>
            <fpage>697</fpage>
            <page-range>697-700</page-range>
            <pub-id pub-id-type="pmid">4291105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rigler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pramanik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jonasson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kratz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jansson</surname>
                <given-names>OT</given-names>
              </name>
              <name>
                <surname>Nygren</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>St&#x000e2;hl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ekberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Uhl&#x000e9;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uhl&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>J&#x000f6;rnvall</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wahren</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Specific binding of proinsulin C-peptide to human cell membranes.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1999</year>
            <month>Nov</month>
            <day>09</day>
            <volume>96</volume>
            <issue>23</issue>
            <fpage>13318</fpage>
            <page-range>13318-23</page-range>
            <pub-id pub-id-type="pmid">10557318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Rasheed</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Willars</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Brunskill</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>C-peptide signals via Galpha i to protect against TNF-alpha-mediated apoptosis of opossum kidney proximal tubular cells.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>986</fpage>
            <page-range>986-95</page-range>
            <pub-id pub-id-type="pmid">16510765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kotova</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Davidescu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ehr&#x000e9;n</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ekberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>J&#x000f6;rnvall</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wahren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chibalin</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>C-peptide stimulates Na+, K+-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells.</article-title>
            <source>Cell Mol Life Sci</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>61</volume>
            <issue>21</issue>
            <fpage>2782</fpage>
            <page-range>2782-90</page-range>
            <pub-id pub-id-type="pmid">15549182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Makondo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ca&#x000f1;as</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sakane</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein.</article-title>
            <source>Biochem J</source>
            <year>2001</year>
            <month>Apr</month>
            <day>01</day>
            <volume>355</volume>
            <issue>Pt 1</issue>
            <fpage>123</fpage>
            <page-range>123-9</page-range>
            <pub-id pub-id-type="pmid">11256956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatt</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>C-peptide activates AMPK&#x003b1; and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes.</article-title>
            <source>Diabetes</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>11</issue>
            <fpage>3851</fpage>
            <page-range>3851-62</page-range>
            <pub-id pub-id-type="pmid">23884890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luppi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cifarelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Piganelli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trucco</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway.</article-title>
            <source>Diabetologia</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>51</volume>
            <issue>8</issue>
            <fpage>1534</fpage>
            <page-range>1534-43</page-range>
            <pub-id pub-id-type="pmid">18493738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wahren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>C-peptide: new findings and therapeutic possibilities.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>309</fpage>
            <page-range>309-19</page-range>
            <pub-id pub-id-type="pmid">25648391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leighton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sainsbury</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>A Practical Review of C-Peptide Testing in Diabetes.</article-title>
            <source>Diabetes Ther</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>475</fpage>
            <page-range>475-487</page-range>
            <pub-id pub-id-type="pmid">28484968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bowman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Hattersley</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes.</article-title>
            <source>Diabet Med</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-3</page-range>
            <pub-id pub-id-type="pmid">21883437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Peake</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Pullan</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Hattersley</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>EDTA improves stability of whole blood C-peptide and insulin to over 24 hours at room temperature.</article-title>
            <source>PLoS One</source>
            <year>2012</year>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>e42084</fpage>
            <pub-id pub-id-type="pmid">22860060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okuno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Komada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sakaguchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hirota</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Seino</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Postprandial serum C-peptide to plasma glucose concentration ratio correlates with oral glucose tolerance test- and glucose clamp-based disposition indexes.</article-title>
            <source>Metabolism</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>62</volume>
            <issue>10</issue>
            <fpage>1470</fpage>
            <page-range>1470-6</page-range>
            <pub-id pub-id-type="pmid">23831440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenbaum</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Mandrup-Poulsen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Battelino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haastert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ludvigsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pozzilli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lachin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kolb</surname>
                <given-names>H</given-names>
              </name>
              <collab>Type 1 Diabetes Trial Net Research Group</collab>
              <collab>European C-Peptide Trial Study Group</collab>
            </person-group>
            <article-title>Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.</article-title>
            <source>Diabetes Care</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>1966</fpage>
            <page-range>1966-71</page-range>
            <pub-id pub-id-type="pmid">18628574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18743.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arzamendi</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Rajamani</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Pseudoinsulinoma in a white man with autoimmune hypoglycemia due to anti-insulin antibodies: value of the free C-Peptide assay.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>142</volume>
            <issue>5</issue>
            <fpage>689</fpage>
            <page-range>689-93</page-range>
            <pub-id pub-id-type="pmid">25319986</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
